Skip to main content
main-content
Erschienen in: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2/2013

01.02.2013 | Originalien und Übersichten

Risiken und fraglicher Nutzen von Nahrungsergänzungsmitteln mit isolierten Isoflavonen für Frauen in und nach der Menopause

verfasst von: Dr. S. Andres, A. Lampen

Erschienen in: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Isolierte Isoflavone werden häufig als Nahrungsergänzungsmittel gegen peri- und postmenopausale Beschwerden angeboten. Diesen aus der Sojapflanze stammenden Pflanzeninhaltsstoffen werden zahlreiche gesundheitliche Effekten nachgesagt wie der Schutz vor Mammakarzinomen, Osteoporose und kardiovaskulären Erkrankungen. Gegenwärtig können jedoch behauptete positive Wirkungen von isolierten Isoflavonen nicht als ausreichend wissenschaftlich belegt angesehen werden. Darüber hinaus wird die Sicherheit dieser Produkte kontrovers diskutiert. Nach Aufnahme hoher Isoflavon-Dosen sind adverse Effekte auf das Brustdrüsengewebe, das Endometrium und die Schilddrüse, Letzteres insbesondere bei bestehendem Jodmangel, nicht auszuschließen. Isoflavone können durch östrogene Effekte möglicherweise einen stimulierenden Einfluss auf bestehende Östrogen-sensitive maligne Zellen aufweisen. Im Fokus der Risikobetrachtung stehen hierbei insbesondere Frauen in und nach der Menopause, da diese die Zielgruppe für Isoflavon-Präparate sind und sie ohnehin ein erhöhtes Brustkrebsrisiko besitzen. Eine längerfristige Gabe von isolierten Isoflavonen insbesondere in höheren Dosierungen ist kritisch zu sehen und sollte zumindest erst nach Aufklärung der Patienten und nicht ohne ärztliche Kontrolle erfolgen.
Literatur
1.
Zurück zum Zitat Andres S, Abraham K, Appel KE, Lampen A (2011) Risks and benefits of dietary isoflavones for cancer. Crit Rev Toxicol 41:463–506 PubMedCrossRef Andres S, Abraham K, Appel KE, Lampen A (2011) Risks and benefits of dietary isoflavones for cancer. Crit Rev Toxicol 41:463–506 PubMedCrossRef
2.
Zurück zum Zitat Mortensen A, Kulling SE, Schwartz H et al (2009) Analytical and compositional aspects of isoflavones in food and their biological effects. Mol Nutr Food Res 53:S266–S309 PubMedCrossRef Mortensen A, Kulling SE, Schwartz H et al (2009) Analytical and compositional aspects of isoflavones in food and their biological effects. Mol Nutr Food Res 53:S266–S309 PubMedCrossRef
3.
Zurück zum Zitat Lunny CA, Fraser SN (2010) The use of complementary and alternative medicines among a sample of Canadian menopausal-aged women. J Midwifery Womens Health 55:335–343 PubMedCrossRef Lunny CA, Fraser SN (2010) The use of complementary and alternative medicines among a sample of Canadian menopausal-aged women. J Midwifery Womens Health 55:335–343 PubMedCrossRef
4.
Zurück zum Zitat Mahady GB, Parrot J, Lee C et al (2003) Botanical dietary supplement use in peri- and postmenopausal women. Menopause 10:65–72 PubMed Mahady GB, Parrot J, Lee C et al (2003) Botanical dietary supplement use in peri- and postmenopausal women. Menopause 10:65–72 PubMed
5.
Zurück zum Zitat Harris PF, Remington PL, Trentham-Dietz A et al (2002) Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 23:501–509 PubMedCrossRef Harris PF, Remington PL, Trentham-Dietz A et al (2002) Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 23:501–509 PubMedCrossRef
6.
Zurück zum Zitat Lammersfeld CA, King J, Walker S et al (2009) Prevalence, sources, and predictors of soy consumption in breast cancer. Nutr J 8:2 PubMedCrossRef Lammersfeld CA, King J, Walker S et al (2009) Prevalence, sources, and predictors of soy consumption in breast cancer. Nutr J 8:2 PubMedCrossRef
7.
Zurück zum Zitat SKLM (2006) Isoflavone als Phytoestrogene in Nahrungsergänzungsmitteln und diätetischen Lebensmitteln für besondere medizinische Zwecke, DFG – Senatskommission zur Beurteilung der gesundheitlichen Unbedenklichkeit von Lebensmitteln (SKLM). http://​www.​dfg.​de/​download/​pdf/​dfg_​im_​profil/​reden_​stellungnahmen/​2006/​sklm_​phytoestrogene_​28112006.​pdf SKLM (2006) Isoflavone als Phytoestrogene in Nahrungsergänzungsmitteln und diätetischen Lebensmitteln für besondere medizinische Zwecke, DFG – Senatskommission zur Beurteilung der gesundheitlichen Unbedenklichkeit von Lebensmitteln (SKLM). http://​www.​dfg.​de/​download/​pdf/​dfg_​im_​profil/​reden_​stellungnahmen/​2006/​sklm_​phytoestrogene_​28112006.​pdf
8.
Zurück zum Zitat BfR (2007) Isolierte Isoflavone sind nicht ohne Risiko, Aktualisierte Stellungnahme Nr. 039/2007 des BfR vom 3. April 2007, Bundesinstitut für Risikobewertung (BfR). http://​www.​bfr.​bund.​de/​cm/​343/​isolierte_​isoflavone_​sind_​nicht_​ohne_​risiko.​pdf BfR (2007) Isolierte Isoflavone sind nicht ohne Risiko, Aktualisierte Stellungnahme Nr. 039/2007 des BfR vom 3. April 2007, Bundesinstitut für Risikobewertung (BfR). http://​www.​bfr.​bund.​de/​cm/​343/​isolierte_​isoflavone_​sind_​nicht_​ohne_​risiko.​pdf
9.
Zurück zum Zitat Klein CB, King AA (2007) Genistein genotoxicity: critical considerations of in vitro exposure dose. Toxicol Appl Pharmacol 224:1–11 PubMedCrossRef Klein CB, King AA (2007) Genistein genotoxicity: critical considerations of in vitro exposure dose. Toxicol Appl Pharmacol 224:1–11 PubMedCrossRef
10.
Zurück zum Zitat Canderelli R, Leccesse LA, Miller NL, Unruh DJ (2007) Benefits of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract 19:635–641 PubMedCrossRef Canderelli R, Leccesse LA, Miller NL, Unruh DJ (2007) Benefits of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract 19:635–641 PubMedCrossRef
11.
Zurück zum Zitat Helferich WG, Andrade JE, Hoagland MS (2008) Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 16:219–226 PubMedCrossRef Helferich WG, Andrade JE, Hoagland MS (2008) Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 16:219–226 PubMedCrossRef
12.
Zurück zum Zitat Jacobs A, Wegewitz U, Sommerfeld C et al (2009) Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review. Mol Nutr Food Res 53:1084–1097 PubMedCrossRef Jacobs A, Wegewitz U, Sommerfeld C et al (2009) Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review. Mol Nutr Food Res 53:1084–1097 PubMedCrossRef
13.
Zurück zum Zitat Lethaby AE, Brown J, Marjoribanks J et al (2007) Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev CD001395 Lethaby AE, Brown J, Marjoribanks J et al (2007) Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev CD001395
14.
Zurück zum Zitat EFSA (2011) Scientific Opinion on the substantiation of health claims related to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245), maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), maintenance of normal skin tonicity (ID 1704a), contribution to normal hair growth (ID 1704a, 4254), „cardiovascular health“ (ID 3587), treatment of prostate cancer (ID 3588) and „upper respiratory tract“ (ID 3589) pursuant to Article 13(1) of Regulation (EC) No 1924/2006; European Food Safety Authority (EFSA); EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). http://​www.​efsa.​europa.​eu/​en/​efsajournal/​doc/​2264.​pdf.​ EFSA J 9:2264 EFSA (2011) Scientific Opinion on the substantiation of health claims related to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245), maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), maintenance of normal skin tonicity (ID 1704a), contribution to normal hair growth (ID 1704a, 4254), „cardiovascular health“ (ID 3587), treatment of prostate cancer (ID 3588) and „upper respiratory tract“ (ID 3589) pursuant to Article 13(1) of Regulation (EC) No 1924/2006; European Food Safety Authority (EFSA); EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). http://​www.​efsa.​europa.​eu/​en/​efsajournal/​doc/​2264.​pdf.​ EFSA J 9:2264
15.
Zurück zum Zitat Evans M, Elliott JG, Sharma P et al (2011) The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas 68:189–196 PubMedCrossRef Evans M, Elliott JG, Sharma P et al (2011) The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas 68:189–196 PubMedCrossRef
16.
Zurück zum Zitat Cassidy A, Albertazzi P, Lise Nielsen I et al (2006) Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc 65:76–92 PubMedCrossRef Cassidy A, Albertazzi P, Lise Nielsen I et al (2006) Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc 65:76–92 PubMedCrossRef
17.
Zurück zum Zitat EFSA (2009) Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) pursuant to Article 13(1) of Regulation (EC) No 1924/2006; European Food Safety Authority (EFSA); EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). http://​www.​efsa.​europa.​eu/​it/​scdocs/​doc/​1270.​pdf.​ EFSA J 7:1270 EFSA (2009) Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) pursuant to Article 13(1) of Regulation (EC) No 1924/2006; European Food Safety Authority (EFSA); EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). http://​www.​efsa.​europa.​eu/​it/​scdocs/​doc/​1270.​pdf.​ EFSA J 7:1270
18.
Zurück zum Zitat Castelo-Branco C, Cancelo Hidalgo MJ (2011) Isoflavones: effects on bone health. Climacteric 14:204–211 PubMedCrossRef Castelo-Branco C, Cancelo Hidalgo MJ (2011) Isoflavones: effects on bone health. Climacteric 14:204–211 PubMedCrossRef
19.
Zurück zum Zitat Taku K, Melby MK, Nishi N et al (2011) Soy isoflavones for osteoporosis: an evidence-based approach. Maturitas 70:333–338 PubMedCrossRef Taku K, Melby MK, Nishi N et al (2011) Soy isoflavones for osteoporosis: an evidence-based approach. Maturitas 70:333–338 PubMedCrossRef
20.
Zurück zum Zitat Wei P, Liu M, Chen Y, Chen DC (2012) Systematic review of soy isoflavone supplements on osteoporosis in women. Asian Pac J Trop Med 5:243–248 PubMedCrossRef Wei P, Liu M, Chen Y, Chen DC (2012) Systematic review of soy isoflavone supplements on osteoporosis in women. Asian Pac J Trop Med 5:243–248 PubMedCrossRef
21.
Zurück zum Zitat Dong JY, Qin LQ (2011) Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat 125:315–323 PubMedCrossRef Dong JY, Qin LQ (2011) Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat 125:315–323 PubMedCrossRef
22.
Zurück zum Zitat Patisaul HB, Jefferson W (2010) The pros and cons of phytoestrogens. Front Neuroendocrinol 31:400–419 PubMedCrossRef Patisaul HB, Jefferson W (2010) The pros and cons of phytoestrogens. Front Neuroendocrinol 31:400–419 PubMedCrossRef
23.
Zurück zum Zitat Aso T, Uchiyama S, Matsumura Y et al (2012) A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women. J Womens Health (Larchmt) 21:92–100 CrossRef Aso T, Uchiyama S, Matsumura Y et al (2012) A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women. J Womens Health (Larchmt) 21:92–100 CrossRef
24.
Zurück zum Zitat Choi EJ, Kim GH (2011) Anticancer mechanism of equol in 7,12-dimethylbenz(a)anthracene-treated animals. Int J Oncol 39:747–754 PubMed Choi EJ, Kim GH (2011) Anticancer mechanism of equol in 7,12-dimethylbenz(a)anthracene-treated animals. Int J Oncol 39:747–754 PubMed
25.
Zurück zum Zitat Goodman MT, Shvetsov YB, Wilkens LR et al (2009) Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Prev Res (Phila) 2:887–894 CrossRef Goodman MT, Shvetsov YB, Wilkens LR et al (2009) Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Prev Res (Phila) 2:887–894 CrossRef
26.
Zurück zum Zitat Jackson RL, Greiwe JS, Schwen RJ (2011) Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist. Nutr Rev 69:432–448 PubMedCrossRef Jackson RL, Greiwe JS, Schwen RJ (2011) Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist. Nutr Rev 69:432–448 PubMedCrossRef
27.
Zurück zum Zitat Tousen Y, Ezaki J, Fujii Y et al (2011) Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause 18:563–574 PubMedCrossRef Tousen Y, Ezaki J, Fujii Y et al (2011) Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause 18:563–574 PubMedCrossRef
28.
Zurück zum Zitat Yoneda T, Ueno T, Uchiyama S (2011) S-equol and the fermented soy product SE5-OH containing S-equol similarly decrease ovariectomy-induced increase in rat tail skin temperature in an animal model of hot flushes. Menopause 18:814–820 PubMedCrossRef Yoneda T, Ueno T, Uchiyama S (2011) S-equol and the fermented soy product SE5-OH containing S-equol similarly decrease ovariectomy-induced increase in rat tail skin temperature in an animal model of hot flushes. Menopause 18:814–820 PubMedCrossRef
29.
Zurück zum Zitat Tempfer CB, Froese G, Heinze G et al (2009) Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med 122:939–946 PubMedCrossRef Tempfer CB, Froese G, Heinze G et al (2009) Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med 122:939–946 PubMedCrossRef
30.
Zurück zum Zitat L’Hocine L, Boye JI (2007) Allergenicity of soybean: new developments in identification of allergenic proteins, cross-reactivities and hypoallergenization technologies. Crit Rev Food Sci Nutr 47:127–143 CrossRef L’Hocine L, Boye JI (2007) Allergenicity of soybean: new developments in identification of allergenic proteins, cross-reactivities and hypoallergenization technologies. Crit Rev Food Sci Nutr 47:127–143 CrossRef
31.
Zurück zum Zitat Patrick L (2008) Iodine: deficiency and therapeutic considerations. Altern Med Rev 13:116–127 PubMed Patrick L (2008) Iodine: deficiency and therapeutic considerations. Altern Med Rev 13:116–127 PubMed
32.
Zurück zum Zitat Rajah TT, Du N, Drews N, Cohn R (2009) Genistein in the presence of 17beta-estradiol inhibits proliferation of ERbeta breast cancer cells. Pharmacology 84:68–73 PubMedCrossRef Rajah TT, Du N, Drews N, Cohn R (2009) Genistein in the presence of 17beta-estradiol inhibits proliferation of ERbeta breast cancer cells. Pharmacology 84:68–73 PubMedCrossRef
33.
Zurück zum Zitat Cline JM, Wood CE (2009) Estrogen/isoflavone interactions in cynomolgus macaques (Macaca fascicularis). Am J Primatol 71:722–731 PubMedCrossRef Cline JM, Wood CE (2009) Estrogen/isoflavone interactions in cynomolgus macaques (Macaca fascicularis). Am J Primatol 71:722–731 PubMedCrossRef
34.
Zurück zum Zitat Hooper L, Madhavan G, Tice JA et al (2010) Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Hum Reprod Update 16:745–760 PubMedCrossRef Hooper L, Madhavan G, Tice JA et al (2010) Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Hum Reprod Update 16:745–760 PubMedCrossRef
35.
Zurück zum Zitat Khan SA, Chatterton RT, Michel N et al (2012) Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila) 5:309–319 CrossRef Khan SA, Chatterton RT, Michel N et al (2012) Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila) 5:309–319 CrossRef
36.
Zurück zum Zitat Singh SP, Wahajuddin, Raju KS et al (2012) Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats. Phytother Res 26:303–307 PubMedCrossRef Singh SP, Wahajuddin, Raju KS et al (2012) Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats. Phytother Res 26:303–307 PubMedCrossRef
37.
Zurück zum Zitat Du M, Yang X, Hartman J A et al (2012) Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis 33:895–901 PubMedCrossRef Du M, Yang X, Hartman J A et al (2012) Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis 33:895–901 PubMedCrossRef
38.
Zurück zum Zitat Guha N, Kwan ML, Quesenberry CP Jr et al (2009) Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 118:395–405 PubMedCrossRef Guha N, Kwan ML, Quesenberry CP Jr et al (2009) Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 118:395–405 PubMedCrossRef
39.
Zurück zum Zitat Shu XO, Zheng Y, Cai H et al (2009) Soy food intake and breast cancer survival. JAMA 302:2437–2443 PubMedCrossRef Shu XO, Zheng Y, Cai H et al (2009) Soy food intake and breast cancer survival. JAMA 302:2437–2443 PubMedCrossRef
40.
Zurück zum Zitat Kang X, Zhang Q, Wang S et al (2010) Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ 182:1857–1862 PubMed Kang X, Zhang Q, Wang S et al (2010) Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ 182:1857–1862 PubMed
41.
Zurück zum Zitat Caan BJ, Natarajan L, Parker B et al (2011) Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 20:854–858 PubMedCrossRef Caan BJ, Natarajan L, Parker B et al (2011) Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 20:854–858 PubMedCrossRef
42.
Zurück zum Zitat Al-Azzawi F, Wahab M (2010) Effectiveness of phytoestrogens in climacteric medicine. Ann N Y Acad Sci 1205:262–267 PubMedCrossRef Al-Azzawi F, Wahab M (2010) Effectiveness of phytoestrogens in climacteric medicine. Ann N Y Acad Sci 1205:262–267 PubMedCrossRef
43.
Zurück zum Zitat This P, Cremoux P de, Leclercq G, Jacquot Y (2011) A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas 70:222–226 PubMedCrossRef This P, Cremoux P de, Leclercq G, Jacquot Y (2011) A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas 70:222–226 PubMedCrossRef
44.
45.
Zurück zum Zitat D’Anna R, Cannata ML, Marini H et al (2009) Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause 16:301–306 CrossRef D’Anna R, Cannata ML, Marini H et al (2009) Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause 16:301–306 CrossRef
46.
Zurück zum Zitat NAMS (2011) The role of soy isoflavones in menopausal health: report of the North American Menopause Society/Wulf H. Utian translational science symposium in Chicago, IL (October 2010). Menopause 18:732–753 CrossRef NAMS (2011) The role of soy isoflavones in menopausal health: report of the North American Menopause Society/Wulf H. Utian translational science symposium in Chicago, IL (October 2010). Menopause 18:732–753 CrossRef
47.
Zurück zum Zitat Pampaloni B, Bartolini S, Bartolini E et al (2009) Absorption and bioeffects of an isoflavone-based supplementation in postmenopausal women. Clin Cases Miner Bone Metab 6:254–260 PubMed Pampaloni B, Bartolini S, Bartolini E et al (2009) Absorption and bioeffects of an isoflavone-based supplementation in postmenopausal women. Clin Cases Miner Bone Metab 6:254–260 PubMed
48.
Zurück zum Zitat Steinberg FM, Murray MJ, Lewis RD et al (2011) Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr 93:356–367 PubMedCrossRef Steinberg FM, Murray MJ, Lewis RD et al (2011) Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr 93:356–367 PubMedCrossRef
49.
Zurück zum Zitat Messina M, Redmond G (2006) Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16:249–258 PubMedCrossRef Messina M, Redmond G (2006) Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16:249–258 PubMedCrossRef
50.
Zurück zum Zitat Sathyapalan T, Manuchehri AM, Thatcher N J et al (2011) The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab 96:1442–1449 PubMedCrossRef Sathyapalan T, Manuchehri AM, Thatcher N J et al (2011) The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab 96:1442–1449 PubMedCrossRef
Metadaten
Titel
Risiken und fraglicher Nutzen von Nahrungsergänzungsmitteln mit isolierten Isoflavonen für Frauen in und nach der Menopause
verfasst von
Dr. S. Andres
A. Lampen
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz / Ausgabe 2/2013
Print ISSN: 1436-9990
Elektronische ISSN: 1437-1588
DOI
https://doi.org/10.1007/s00103-012-1604-2

Weitere Artikel der Ausgabe 2/2013

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2/2013 Zur Ausgabe

Newsletter

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Allgemeinmedizin und bleiben Sie gut informiert – ganz bequem per eMail.